BRVE vs ETON: stock comparison and AI forecast
Braveheart Bio, Inc. (BRVE) and Eton Pharmaceuticals, Inc. (ETON) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BRVE Braveheart Bio, Inc.
- Market Cap
- $1.42B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
ETON Eton Pharmaceuticals, Inc.
- Market Cap
- $1.35B
- P/E Ratio
- 47.6x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- BRVE and ETON have similar market capitalizations ($1.42B and $1.35B).
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BRVE | ETON |
|---|---|---|
| Market Cap | $1.42B | $1.35B |
| P/E Ratio | – | 47.63x |
| P/B Ratio | – | 15.50x |
| EPS | – | $0.99 |
| Book Value/Share | – | $3.04 |
| Revenue/Share | – | $2.77 |
| FCF/Share | – | $1.34 |
Profitability & Margins
| Metric | BRVE | ETON |
|---|---|---|
| ROIC | – | 39.4% |
| Operating Margin | – | 51.4% |
| EBT Margin | – | 46.8% |
| Tax Rate | – | -35.0% |
Financial Health
| Metric | BRVE | ETON |
|---|---|---|
| Current Ratio | 13.63x | 1.79x |
| Quick Ratio | – | 1.58x |
| D/E Ratio | – | 0.81x |
| Financial Leverage | – | 1.81x |
| Interest Coverage | – | 9.6x |
| Working Capital | $114M | $43M |
Cash Flow
| Metric | BRVE | ETON |
|---|---|---|
| Operating Cash Flow | – | $38M |
| Free Cash Flow | – | $38M |
| Capital Spending | – | -$130K |
| OCF Growth YoY | – | 80.0% |
| FCF Growth YoY | – | 81.9% |
| FCF/Sales | – | 48.2% |
| CapEx/Sales | – | 0.2% |
Operational Efficiency
| Metric | BRVE | ETON |
|---|---|---|
| Asset Turnover | – | 0.50x |
| Receivables Turnover | – | 3.0x |
| Inventory Turnover | – | 3.9x |
| Fixed Assets Turnover | – | 234.3x |
| Days Sales Outstanding | – | 122 days |
| Days Inventory | – | 93 days |
| Payables Period | – | 138 days |
| Cash Conversion Cycle | – | 76 days |
Income Statement
| Metric | BRVE | ETON |
|---|---|---|
| Total Revenue | – | $79M |
| Operating Income | – | $41M |
| R&D Expense | – | $10M |
| Cost of Goods Sold | – | $44M |
Dividend & Shareholder Information
| Metric | BRVE | ETON |
|---|---|---|
| Shares Outstanding | 82M | 29M |
BRVE vs ETON: stock comparison and AI forecast
Which is bigger, BRVE or ETON?
BRVE and ETON have similar market capitalizations ($1.42B and $1.35B).
Which one does Intratio's AI model rank higher, BRVE or ETON?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.